This study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. fT\> 100% MIC) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Rate of adherence to the sampling protocol
Timeframe: At 24 hours of treatment of piperacillin-tazobactam after randomization
Recruitment rate
Timeframe: At the randomization
Achievement of a prespecified number of patients recruited per month
Timeframe: At the randomization
Proportion of eligible patients relative to the total population who received a piperacillin-tazobactam for the study period
Timeframe: From the screening period to the enrollment, assessed up to 24 hours after the start of a piperacillin-tazobactam prescription